Pharmaceuticals

We support prescription and OTC pharmaceutical products with a cost-effective approach from development through commercial production.

Inner banner
Built for global regulation

End-to-end quality in GMP execution

Prescription and OTC drug products require controlled GMP execution supported by defined procedures, ICH-aligned specifications, and a stability program matched to shelf life. We connect development, analytical testing, and manufacturing so batch documentation and quality oversight stay aligned as the project advances.

Technical alignment for scale‑up

Our approach is to align technical decisions with process control strategy early, then carry that discipline through manufacturing, testing, and batch release as the project scales.

QbD STRATEGY 

CQAs, CPPs, and specifications defined to meet product requirements and lifecycle stages.

BATCH RECORDS, TESTING, AND RELEASE

Batch documentation, release testing, and review executed consistently to support timely release.

DEVIATIONS, CAPA, AND CHANGE CONTROL

Robust quality processes that support controlled evolution of the process and product over time.

QbD-driven lifecycle

We apply a QbD approach to define critical attributes, establish control strategy, and sustain GMP monitoring.

Card 01

DEFINE QTPP AND CQA

We define the Quality Target Product Profile (QTPP) and the Critical Quality Attributes (CQAs) that guide process development and decisions for clinical and commercial supply.

Card 02

PROCESS Parameters

We identify Critical Process Parameters (CPPs) and establish process controls, sampling plans, and procedures that keep manufacturing execution within validated ranges.

Card 03

ANALYTICAL STRATEGY

We set release and stability specifications, including tests and acceptance criteria, and define an analytical strategy aligned with ICH expectations for drug product.

Card 04

PROCESS VALIDATION

We support process validation across the lifecycle, including process design, PPQ, and continued process verification, to demonstrate consistent performance.

Card 05

BATCH RECORDS

We generate GMP manufacturing batch records and execute Quality Unit review for disposition, supported by release testing performed against final specifications.

Our Capabilities

We develop and manufacture prescription and OTC drug products to meet market and regulatory requirements.

Prescription
Prescription

Prescription products rely on defined controls, clear documentation, and Quality Unit oversight that supports consistent batch disposition across lifecycle stages.

  • Formulation, reverse engineering, and comparative assessment to support 505(b)(2) and generic development decisions.
  • Tech transfer, scale-up, and validation executed with specification-driven testing.
OTC
OTC

OTC products benefit from GMP execution focused on efficient, cost‑effective manufacturing, helping clients meet pricing expectations and deliver compliant products to the market.

  • Formulation, reverse engineering, and reference product benchmarking to guide OTC development and positioning.
  • Formulation and process optimization support change control required for the product improvement or to meet stability targets, and manufacturability.

Our Services

Integrated services that move non-sterile prescription and OTC programs from development through batch release.

01
Layer_1 (3)-1
Product Development

Turns target performance into a formulation and control strategy suitable for GMP scale-up and lifecycle changes.

02
Icons (1)-2
Analytical Services

Confirm product conformance through method validation and QC testing aligned to release and stability requirements.

03
Icons (2)-1
Manufacturing & Packaging

Deliver repeatable GMP batches using defined procedures, in-process controls, and Quality Unit review.

We support non-sterile prescription and OTC products with GMP execution, backed by strong analytical support and quality review.

Resources

Explore practical guidance for non-sterile prescription and OTC programs, from development through batch release.

Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development
Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development

Contact Us

Need a CDMO for non-sterile prescription or OTC products?

Let’s talk about your product needs. Share your project scope, and we will follow up with the next steps.